PG-102 clinical trials
Also written PG-102.
How each study uses PG-102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PG-102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
ProGen. Co., Ltd. (4) · Seoul National University Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test PG-102.
- May 2027Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPhase 2 · ProGen. Co., Ltd.
Studies
Open first, then newest update. How each study uses PG-102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNot yet recruitingPhase 2ProGen. Co., Ltd.NCT07677891Written as PG-102(MG12)
- Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes MellitusNot yet recruitingPhase 2ProGen. Co., Ltd.NCT07187856Written as PG-102
- Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesActive, not recruitingPhase 2ProGen. Co., Ltd.NCT06712615Written as PG-102
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.CompletedPhase 1ProGen. Co., Ltd.NCT06309667Written as PG-102(MG12)
- The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE LevelsCompletedPhase 2Seoul National University HospitalNCT01106703Written as PG102, a water soluble extract from Actinidia arguta